Nymox Pharmaceutical Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	0.07	0.07	1.4	0.83	3.61
Cash & Short-Term Investments	0.07	0.07	1.4	0.83	3.61
Cash Growth	5.71%	-95.01%	69.04%	-77.02%	-31.08%
Other Receivables	0.03	0.01	0.01	0.01	0.02
Receivables	0.03	0.01	0.01	0.01	0.02
Inventory	-	-	-	0.03	0.03
Prepaid Expenses	0.02	0.02	0.02	0.13	0.2
Other Current Assets	0.54	0.53	0.03	0.03	0.03
Total Current Assets	0.65	0.63	1.46	1.04	3.89
Property, Plant & Equipment	0	0	0.17	0.41	0.45
Total Assets	0.65	0.63	1.63	1.44	4.34
Accounts Payable	4.12	3.02	1.7	1.27	1.4
Accrued Expenses	0.03	0.03	0.24	0.29	0.32
Short-Term Debt	3.29	0.75	-	-	-
Current Portion of Leases	-	-	0.17	0.23	0.19
Other Current Liabilities	-	-	-	-	0.05
Total Current Liabilities	7.43	3.8	2.11	1.79	1.97
Long-Term Leases	-	-	-	0.16	0.23
Total Liabilities	7.43	3.8	2.11	1.95	2.2
Common Stock	173.88	173.82	171.67	165.06	151.72
Additional Paid-In Capital	28.01	27.78	26.99	27.58	31.04
Retained Earnings	-212.47	-207.98	-199.14	-192.56	-180.03
Comprehensive Income & Other	3.81	3.21	-	-0.59	-0.59
Total Common Equity	-6.78	-3.17	-0.48	-0.51	2.15
Shareholders' Equity	-6.78	-3.17	-0.48	-0.51	2.15
Total Liabilities & Equity	0.65	0.63	1.63	1.44	4.34
Total Debt	3.29	0.75	0.17	0.39	0.43
Net Cash (Debt)	-3.21	-0.68	1.23	0.44	3.19
Net Cash Growth	-	-	180.18%	-86.22%	-37.45%
Net Cash Per Share	-0.03	-0.01	0.01	0.01	0.04
Filing Date Shares Outstanding	94.54	93.54	91.27	90.28	78.71
Total Common Shares Outstanding	94.54	93.54	90.52	85.55	77.96
Working Capital	-6.78	-3.18	-0.65	-0.75	1.93
Book Value Per Share	-0.07	-0.03	-0.01	-0.01	0.03
Tangible Book Value	-6.78	-3.17	-0.48	-0.51	2.15
Tangible Book Value Per Share	-0.07	-0.03	-0.01	-0.01	0.03
Machinery	0.6	0.6	0.59	0.59	0.59

Updated Jan 2, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.